[1] MYTILINAIOU M,KYROU I,KHAN M,et al.Familial hypercholesterolemia:new horizons for diagnosis and effective management[J].Front Pharmacol,2018,9:707.
[2] 中华医学会心血管病学分会动脉粥样硬化及冠心病学组,中华心血管病杂志编辑委员会.家族性高胆固醇血症筛查与诊治中国专家共识[J].中华心血管病杂志,2018,46(2):99-103.
[3] 冯领周,王建梅,陈玉红,等.青年冠心病可控危险因素与冠脉Gensini积分相关性分析[J].现代医学,2015,43(6):706-710.
[4] NORDESTGARD B G,CHAPMAN M J,HUMPHRIES S E,et al.Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population:guidance for clincians to prevent coronary heart disease:consensus statement of the European Atherosclerosis Society[J].Eur Heart J,2013,34(45):3478-3490.
[5] 王爱玲,徐岩,程景林.20岁青年家族性高胆固醇血症合并心肌梗死一例[J].中华心血管病杂志,2006,34(1):80-81.
[6] GOLDMANN R,TICHY L,FREIBERGER T,et al.Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia[J].BMC Med Genet,2010,11:115.
[7] FAHED A C,SAFA R M,HADDAD F F,et al.Homozygous familial hypercholesterolemia in Lebanon:a genotype/phenotype correlation[J].Molec Genet Metabol,2011,102(2):181-188.
[8] 方明华,杨丽丽,吕文山.家族性高胆固醇血症分子遗传学机制及干预进展[J].国际遗传学杂志,2019,42(3):234-238.
[9] SHI Z,YUAN B,ZHAO D.Familial hypercholesterolemia in China:prevalence and evidence of underdetection and undertreatment in a community population[J].Int J Cardiol,2014,174(3):834-836.
[10] BROEKHUIZEN K,JELSMA G J,VAN POPPEL N M.Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviors in people with familial hypercholesterolemia?[J].BMC Public Health,2012,12:348.
[11] 崔淯夏,梁文卿,李素芳,等.家族性高胆固醇血症的诊断现状与挑战[J].中华老年心脑血管杂志,2019,21(7):766-768.
[12] MISEREZ A R,MARTIN F J,SPIRK D.Diagnosis and management of familial hypercholesterolemia in a nationwide design(DIA-MOND-FH):prevalence in switzerland.clinical characteristics and the diagnostic value of clinical scores[J].Atheroselerosis,2018,277:282-288.
[13] SETIA N,SAXENA R,SAWHNEY J,et al.Faimilal hypercholesterolemia:cascade screening in children and relatives of the affected[J].Indian J Pediatr,2018,85(5):339-343.
[14] GRUNDY S M,STONE N J,BAILEY A L,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of the american college of cardiology/american heart association task force on clinical practice guidelines[J].Circulation,2019,139(25):e1082-e1143.
[15] 王丽娟,卜庆梅.家族性高胆固醇血症及其病理、诊断和治疗研究进展[J].生物学教学,2017,42(6):2-3.
[16] YADV K,SHARMA M,FERDINAND K C.Proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitors:present perspectives and future horizons[J].Nutr Metab Cardiovasc Dis, 2016,26(10):853-862.
[17] VAN DER GRAAF A,AVIS H J,KUSTERS D M.Molecular basis of autosomal dominant hypercholesterolemia:assessment in a large cohort of hypercholesterolemia children[J].Circulation,2011,123(11):1167-1173.
[18] CAI M,LI S,SHUAI Y,et al.Genome-wide CRISPR-Cas9 viability screen reveals genes involved in TNF-α-induced apoptosis of human umbilical vein endothelial cells[J].J Cell Physiol,2019,234(6):9184-9193.
[19] MOINI M,MISTRY P,SCHIKKY M L.Liver transplantation for inhedted metabolic disorders of the liver[J].Curr Opin Organ Tranplant,2010,15:269-276.
[20] 王绿娅,胡大一.家族性高胆固醇血症:建立全球统一战线迫在眉睫[J].中华心血管病杂志,2016,44(1):5-6. |
